Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

16
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
16
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

24
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
24
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

32
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
32
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

25
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
25
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

27
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
27
Heart Valves01:16

Heart Valves

5.3K
The human heart is a complex organ with an intricate system of valves that regulate blood flow. There are two main types of valves: atrioventricular (AV) valves and semilunar valves.
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Residual Mitral Regurgitation and Gradient After M‑TEER: 1‑Year Outcomes From the CLASP IID Trial.

JACC. Cardiovascular imaging·2026
Same author

Postoperative outcomes of Morel-Lavallee injuries and predictive factors for wound complications: A Pacific Coast Surgical Association multicenter study.

Surgery·2026
Same author

Prognostic Factors Associated With Mortality Among Patients With Necrotizing Soft-Tissue Infection: A Systematic Review and Meta-Analysis.

Critical care medicine·2026
Same author

Tricuspid Transcatheter-Edge-to-Edge-Repair and Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation: Patient Profiles and Outcomes.

CJC open·2026
Same author

Operative Strategies and Wound Complications for Morel-Lavallee Injuries Undergoing Excisional Debridement: A Pacific Coast Surgical Association Multicenter Study.

The American surgeon·2026
Same author

Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial.

Circulation. Cardiovascular interventions·2026

Related Experiment Video

Updated: Aug 15, 2025

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

2.9K

Congenital Pulmonic Valve Dysfunction Treated With SAPIEN 3 Transcatheter Heart Valve (from the COMPASSION S3 Trial).

D Scott Lim1, Dennis Kim2, Jamil Aboulhosn3

  • 1Departments of Medicine & Pediatrics, University of Virginia, Charlottesville, Virginia.

The American Journal of Cardiology
|January 6, 2023
PubMed
Summary

The SAPIEN 3 transcatheter heart valve (THV) is safe and effective for treating pulmonary regurgitation and stenosis after congenital heart defect surgery. One-year follow-up showed a low rate of THV dysfunction, demonstrating good clinical outcomes.

More Related Videos

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
09:57

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement

Published on: January 20, 2022

2.7K
A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.0K

Related Experiment Videos

Last Updated: Aug 15, 2025

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

2.9K
Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
09:57

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement

Published on: January 20, 2022

2.7K
A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.0K

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Congenital Heart Disease

Background:

  • Pulmonary regurgitation (PR) and stenosis are frequent complications following surgical repair of congenital heart defects.
  • Dysfunctional right ventricular outflow tract (RVOT) conduits or pulmonic valves necessitate effective treatment options.

Purpose of the Study:

  • To evaluate the safety and efficacy of SAPIEN 3 transcatheter heart valve (THV) implantation in patients with dysfunctional RVOT conduits or pulmonic valves.
  • To assess the primary end point of THV dysfunction at one year, including RVOT reintervention, moderate or severe PR, and elevated RVOT gradient.

Main Methods:

  • A prospective, single-arm, multicenter trial enrolled 58 patients undergoing SAPIEN 3 THV implantation.
  • The primary end point was a composite of THV dysfunction at 1 year, with a prespecified performance goal.
  • Data collected included device success at discharge, adverse events at 30 days, and primary end point components at 1 year.

Main Results:

  • Device success at discharge was high at 98.1%.
  • At one year, the primary end point composite occurred in 4.3% of patients, significantly below the performance goal.
  • No mortality, endocarditis, thrombosis, or stent fracture were reported at one year.

Conclusions:

  • The SAPIEN 3 THV demonstrated safety and effectiveness in patients with dysfunctional RVOT conduits or pulmonic valves up to one year post-implantation.
  • These findings support the use of SAPIEN 3 THV as a viable treatment option for this patient population.